BioVie Inc. announced data from presentations at the ATMRD Congress, outlining the protocol design of SUNRISE-PD Phase 2 trial for bezisterim in Parkinson's disease.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
BioVie Inc. announced data from presentations at the ATMRD Congress, outlining the protocol design of SUNRISE-PD Phase 2 trial for bezisterim in Parkinson's disease.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.